Business Information
The company's principal activity is to discover, develop and commercialize oral drugs to treat infectious diseases. The company's pharmaceutical platform develops drugs to treat infections such as fungal diseases, malaria, tuberculosis, hepatitis c and pneumocystis carinii pneumonia and tropical diseases such as trypanosomiasis (african sleeping sickness) and leishmaniasis. Its lead compound db289 has entered human clinical trials including a phase iia trial for the treatment of malaria, a phase iia trial for the treatment of pneumocystis carinii pneumonia and phase iib trial for the treatment of african sleeping sickness. The company also has licensing and exclusive commercialization rights to a dicationic pharmaceutical platform for developing anti-infective oral drugs.
|
|
Name |
Title
|
Email
|
| Eric Sorkin | Chmn., CEO | N/A | | Gary Parks | CFO, Sec., Treasurer | N/A | | Carol Ann Olson | Sr. VP - Pharmaceutical Development, Chief Medical Officer | N/A | | Daniel Schmitt | VP - Licensing, Commercial Development | N/A | | Lawrence Potempa | VP - Research, Chief Scientific Officer | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 3,575 | (15,525) | | 2005 | 5,931 | (13,433) | | 2004 | 2,416 | (12,846)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
